Marck Biosciences forays into Singapore,Malaysia

Image
BS Reporter Mumbai/ Ahmedabad
Last Updated : Jan 20 2013 | 8:02 PM IST

Marck Biosciences, manufacturer and marketer of sterile dosages pharma products and blow-fill-seal specialist, is planning to enter the Singapore and Malaysian market. The manufacturing of the company has received an approval from the National Pharmaceutical Control Bureau (NPCB), ministry of health, Malaysia for large volume parenterals, small volume parenterals and ophthalmics. Marck is the only company in India to have received the NPCB approval for its small volume parenterals facility.

Marck, which has presence in about 70 countries across the world, plans to introduce a range of small volume parenterals including ophthalmics, irrigation solutions, injectibles and respiratory solutions, and IV parenterals formulations in the large volume parenterals in Singapore and Malaysia.

Bhavesh Patel, managing director, Marck Biosciences, said, "The NPCB approval has significant implications for Marck. First, our early entry into Malaysia and Singapore opens up a large export market for our products. Second, the manufacturers of these countries can now get their brands outsourced from Marck. Third, since NPCB is a participant of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) - which has 36 participating authorities including those from UK and Australia, the approval will help our registrations endeavor in other PIC/S member countries."

"With the NPCB approval and the SVP and LVP capacity at our Kheda facility, we will efficiently cater to Malaysia, Singapore and Brunei with our vast product range. A strong marketing, sales and distribution team will be put in force by our South East Asia head to accelerate the penetration planned," Patel added.

According to the company, the South-East Asian countries represent a total market of 588 million people and a combined GDP of $2.2 billion. Marck Biosciences' manufacturing facilities are certified by many international regulatory authorities including the ANVISA from Brazil.

The company's manufacturing facility, located at Kheda near Ahmedabad is spread over an area of 25 acres. The plant, equipment and systems have been designed to meet ISO compliance and Good Manufacturing Practices (GMP) as specified by WHO.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 17 2009 | 12:31 AM IST

Next Story